CB 2 Cannabinoid Receptors as a Therapeutic Target - What does the Future Hold ? Amey Dhopeshwarkar and Ken Mackie Molecular Pharmacology, 2014, 86, 430–437 http://dx.doi.org/10.1124/mol.114.094649 ABSTRACT The past decades have seen an exponential rise in our understanding of the endocannabinoid system, comprising CB1 and CB2 cannabinoid receptors, endogenous cannabinoids (endocannabinoids), and the enzymes that synthesize and degrade endocannabinoids. The primary focus of this review is the CB2 receptor. CB2 receptors have been the subject of considerable attention, primarily due to their promising therapeutic potential for treating various pathologies while avoiding the adverse psychotropic effects that can accompany CB1 receptor–based therapies. With the appreciation that [...]
Lire la suiteBeta-caryophyllene is a dietary cannabinoid Jürg Gertsch, Marco Leonti, Stephan Raduner, Ildiko Racz, Jian-Zhong Chen, Xiang-Qun Xie, Karl-Heinz Altmann, Meliha Karsak and Andreas Zimmer PNAS (Proceedings of the National Academy of Sciences of the USA), 2008, 105, (26), 9099-9104. Doi : 10.1073/pnas.0803601105 Abstract The psychoactive cannabinoids from Cannabis sativa L. and the arachidonic acid-derived endocannabinoids are nonselective natural ligands for cannabinoid receptor type 1 (CB1) and CB2 receptors. Although the CB1 receptor is responsible for the psychomodulatory effects, activation of the CB2 receptor is a potential therapeutic strategy for the treatment of inflammation, pain, atherosclerosis, and osteoporosis. Here, we report that the widespread plant volatile [...]
Lire la suiteAn Overview of Galenic Preparation Methods for Medicinal Cannabis Luigi Romano and Arno Hazekamp Current Bioactive Compounds, 2018, 14, DOI: 10.2174/1573407214666180612080412 Abstract : In recent years, the Cannabis plant (Cannabis sativa L.) has been rediscovered as a source of new medicines around the world. Despite the fact that a number of registered medicines have been developed on the basis of purified cannabis components, there is a rapid increasing acceptance and use of cannabis in its herbal form. Licensed producers of high quality cannabis plants now operate in various countries including The Netherlands, Canada, Israel, and Australia, and in many US states. The legal availability of [...]
Lire la suiteCannabinoid CB1 and CB2 Receptor Signaling and Bias Mikkel Soes Ibsen, Mark Connor, Michelle Glass Cannabis and Cannabinoid Research, 2017, Volume 2.1, 48-60 https://doi.org/10.1089/can.2016.0037 Abstract An agonist that acts through a single receptor can activate numerous signaling pathways. Recent studies have suggested that different ligands can differentially activate these pathways by stabilizing a limited range of receptor conformations, which in turn preferentially drive different downstream signaling cascades. This concept, termed “biased signaling” represents an exciting therapeutic opportunity to target specific pathways that elicit only desired effects, while avoiding undesired effects mediated by different signaling cascades. The cannabinoid receptors CB1 and CB2 each activate multiple pathways, [...]
Lire la suiteMedical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems. A Clinical Review Kevin P. Hill JAMA, 2015, 313, (24), 2474-2483. doi:10.1001/jama.2015.6199 This article is based on a conference that took place at theMedicine Grand Rounds at Beth Israel Deaconess Medical Center, Boston, Massachusetts, on May 16, 2014. IMPORTANCE : As of March 2015, 23 states and the District of Columbia had medical marijuana laws in place. Physicians should know both the scientific rationale and the practical implications for medical marijuana laws. OBJECTIVE : To review the pharmacology, indications, and laws related to medical marijuana use. EVIDENCE REVIEW : The medical literature on medical [...]
Lire la suiteMedical Marijuana Use in Oncology : A Review Gianna Wilkie, Bachir Sakr, Tina Rizack JAMA Oncology, 2016, 2, (5), 670-675. doi:10.1001/jamaoncol.2016.0155 IMPORTANCE : Medicinal marijuana use is currently legal in 23 states and the District of Columbia. As more states approve marijuana use for medical indications, physicians will be asked by their patients for more information regarding the risks and benefits of use. This article reviews the history, adverse effects, and proposed mechanisms of action of marijuana and summarizes the available literature regarding symptom relief and therapeutic value in patients with cancer. OBSERVATIONS : Marijuana in oncologymay have potential for use as an antiemetic, for [...]
Lire la suiteMedical Use of Cannabis in 2019 Kevin P. Hill, MD, MHS JAMA, Published online August 9, 2019 doi:10.1001/jama.2019.11868 Nearly 10% of cannabis users in the United States report using it for medicinal purposes.1 As of August 2019, 33 states and the District of Columbia have initiated policies allowing the use of cannabis or cannabinoids for the management of specific medical conditions. Yet, the federal government still classifies cannabis as illegal, complicating its medical use and research into its effectiveness as a treatment for the various conditions purported to benefit from cannabis pharmacotherapy. Because of this conflict and restrictions on cannabis research, evidence of the [...]
Lire la suiteCannabis à usage thérapeutique, la longue marche, Dr Bertrand Lebeau-Leibovici, UFCM, Strasbourg, 28 juin 2019
Lire la suiteOpioïdes : le cannabidiol pour réduire la dépendance ? Le cannabidiol (CBD) réduit le craving et l'anxiété chez les personnes ayant des antécédents d'abus d'héroïne/opioïdes, suggérant un rôle possible du cannabis ou de son agent le cannabidiol dans la réduction de la dépendance aux opioïdes. C’est la conclusion de cette étude réalisée à l’Icahn School of Medicine du Mont Sinaï (New York), présentée dans l'American Journal of Psychiatry. L'étude confirme également les effets anti-stress du CBD avec une baisse de la fréquence cardiaque et du taux de cortisol induites par les stimuli de drogues. La grande disponibilité des opioïdes sur prescription ces [...]
Lire la suiteIntroduction, 24e Journées du RESPADD "Usages thérapeutiques des cannabinoïdes", Session du GRECC, Docteur Christian Sueur, 26 juin 2019, Paris Bonjour Bienvenu à toutes et à tous Merci d’être venus aussi nombreux à ce premier colloque co-organisé par le GRECC et le RESPADD sur le thème du Cannabis Thérapeutique, ou, de façon « dépassionnée », sur les Usages Cliniques des Cannabinoïdes. Je veux tout d’abord remercier Nicolas Bonnet, Anne Borgne et le RESPADD de nous avoir invité à leur colloque annuel, de nous avoir donné offert cette première demie journée, et d’avoir invité de nombreux intervenants que nous avons proposés pour ces 2 jours de rencontres cannabiques. Le GRECC (Groupe de [...]
Lire la suite